Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of KDEL Receptors Remodels the Tumor Microenvironment for T Cell Independent Tumor Regression.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

A PML1-CCL5-PI3K/MAPK feedback loop governs survival of endocrine-resistant breast cancer cells.

Cell death and differentiation·2026
Same author

Structural insights into cobalamin loading and reactivation of human methionine synthase.

Nature communications·2026
Same author

Structure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolism.

The EMBO journal·2026
Same author

Gut microbe-derived <i>N</i>-acyl serinol lipids shape host postprandial metabolic homeostasis.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

dCas9 Targeted Proteome Profiling Reveals p300-Mediated Reciprocal Regulation of SMAD and SP1 as a Driver of GM2-synthase Transcription in Renal Cell Carcinoma.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026

Related Experiment Video

Updated: Sep 9, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

MCL1 may not mediate chemoresistance.

Kylin A Emhoff1, Kunho Chung1, Dongmei Zhang2

  • 1Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic Research, Cleveland, OH.

Biorxiv : the Preprint Server for Biology
|September 5, 2025
PubMed
Summary
This summary is machine-generated.

MCL1 protein does not appear to enhance chemoresistance or move to the nucleus during cancer drug treatment, contrary to prior research. Further studies are needed to understand MCL1's nuclear functions.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Related Experiment Videos

Last Updated: Sep 9, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • The anti-apoptotic BCL2 family member MCL1 is frequently overexpressed in cancers and associated with treatment resistance.
  • MCL1 has known mitochondrial functions and proposed nuclear roles in chemoresistance, cell cycle, and DNA repair.

Purpose of the Study:

  • To investigate the proposed nuclear functions of MCL1 in chemoresistance.
  • To determine if MCL1 translocates to the nucleus and influences chemoresistance during chemotherapy.

Main Methods:

  • Utilized a newly validated monoclonal antibody against MCL1 in various cancer cell lines.
  • Employed proximity biotinylation to identify nuclear MCL1 interactors.
  • Assessed MCL1 localization and its impact on chemoresistance following drug exposure.

Main Results:

  • No evidence was found that MCL1 enhances chemoresistance or accumulates in the nucleus post-drug treatment.
  • Novel nuclear MCL1 interactors were identified, but previously reported DNA repair and cell cycle partners were not recovered.
  • Data do not support a role for MCL1 in conferring chemoresistance through nuclear mechanisms.

Conclusions:

  • The study challenges previous findings implicating nuclear MCL1 in chemoresistance.
  • MCL1's nuclear translocation and interaction with DNA repair proteins during chemotherapy were not observed.
  • Further research is required to elucidate the functional significance of nuclear MCL1.